Abstract

PURPOSE OF REVIEW

To highlight the respiratory syncytial virus (RSV) disease burden and the current developments and challenges in RSV prevention for older adults ≥60 years through analysis of RSV epidemiology and the effectiveness of emerging vaccines.

RECENT FINDINGS

In industrialized countries, RSV incidence rates and hospitalization rates among older adults are estimated to be 600.7 cases per 100 000 person-years and 157 hospitalizations per 100 000 person-years, respectively. Yet, accurately determining RSV morbidity and mortality in older adults is challenging, thus resulting in substantially under-estimating the disease burden. The in-hospital fatality rates vary substantially with age and geographies, and can be as high as 9.1% in developing countries. Two promising RSV vaccines for the elderly have been approved, demonstrating efficacies of up to 94.1%, signifying considerable advancement in RSV prevention. However, concerns over potential side effects remain.

SUMMARY

RSV is associated with a significant burden in older adults. While the landscape of RSV prevention in older adults is promising with the licensure of vaccines from two companies, current trial data underscore the need for additional studies. Addressing the real-world effectiveness of these vaccines, understanding potential rare side effects, and ensuring broad inclusivity in future trials are crucial steps to maximize their potential benefits.

MeSH

Respiratory Syncytial Viruses, Hospitalization, Vaccines, Viruses, Cost Of Illness, Communicable Diseases

Cited by

• Editorial: Surveillance of Seasonal Respiratory Syncytial Virus (RSV) Infection in Children and Vulnerable Adults Drives Vaccine Development and New Immunization Programs. Med Sci Monit, 2025
• Epidemiology and genetic diversity of respiratory syncytial virus in adults 50 years and older with acute respiratory infections in Accra, Ghana. BMC Infect Dis, 2025
• Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options. Vaccines (Basel), 2025
• Aging enhances pro-atrogenic gene expression and skeletal muscle loss following respiratory syncytial virus infection. Geroscience, 2025
• Respiratory syncytial virus (RSV) infections in adults: Current trends and recommendations for prevention - a global challenge from a local perspective. Hum Vaccin Immunother, 2025
• Prevention of respiratory syncytial virus disease across the lifespan in Italy. Pneumonia (Nathan), 2025
• MARCH8 Restricts RSV Replication by Promoting Cellular Apoptosis Through Ubiquitin-Mediated Proteolysis of Viral SH Protein. Viruses, 2025
• Respiratory syncytial virus-attributable hospitalizations among adults in high- and middle-income countries: application of the Global Burden of Disease framework. EClinicalMedicine, 2025
• Ten-Year Surveillance of Respiratory Syncytial Virus Hospitalizations in Adults: Incidence Rates and Case Definition Implications. J Infect Dis, 2025
• Molecular characterization of human respiratory syncytial virus in Mexico (season 2023-2024) through whole-genome sequencing. Sci Rep, 2025
• COVID-19, Influenza, and RSV in Children and Adults: A Clinical Comparative Study of 12,000 Cases. J Clin Med, 2024
• Enhanced susceptibility of pediatric airway epithelium to respiratory syncytial virus infection. J Clin Invest, 2024
• Recent advances in the prevention and treatment of respiratory syncytial virus disease. J Gen Virol, 2025
• The tricky second album: Licensure of an mRNA vaccine for respiratory syncytial virus. Mol Ther, 2024